Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22692162 | 0.88 | AKR1B1 (0.37) | AKR1B1MPILMNAL3MBTL1 | |
| SCHEMBL309709 | 0.84 | LMNA (0.39) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL458623 | 0.84 | LMNA (0.39) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL8857020 | 0.84 | LMNA (0.39) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL14409028 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL1367677 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL2635114 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL7151920 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL3408591 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 | |
| SCHEMBL4288124 | 0.80 | AKR1B1 (0.34) | AKR1B1MPILMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789030-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024492-A2 | MEDICAL IMPLANT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2006-02-02 | — | — | US | claimed |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2005-02-24 | — | — | US | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4582080-A1 | DISPENSER FOR MUCOSAL ADMINISTRATION COMPRISING 2-DEOXY-GLUCOSE OR ANALOGUES THEREOF | G.ST Antivirals GmbH (AT) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20050020682-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-01-27 | — | — | US | disclosed |
| WO-2004111199-A2 | SYSTEMS AND METHODS FOR TREATING HUMAN INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS, WITH FATTY ACID METABOLISM INHIBITORS AND/OR GLYCOLYTIC INHIBITORS | UNIVERSITY OF COLORADO SYSTEM TECHNOLOGY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6670330-B1 | Treating human breast cancer | LAMPIDIS THEODORE J (US) | 2003-12-30 | — | — | US | disclosed |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | AKR1B1 924/4885MPI 365/4885LMNA 3656/4885 |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | AKR1B1 2102/4885MPI 193/4885LMNA 4786/4885 |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885MPI 225/4885LMNA 4687/4885 |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885MPI 225/4885LMNA 4687/4885 |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | AKR1B1 128/4885MPI 225/4885LMNA 4687/4885 |
| US-20050020682-A1 | Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors | FASN, G6PD, HK2 | AKR1B1 200/4885MPI 867/4885LMNA 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.